4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Alzamend Neuro, Inc. (ALZN) operates in the Biotechnology industry and is headquartered in Atlanta, United States with about 4 employees. Its market capitalization is roughly $5 million. In the fiscal year ended 2026-04-30, ALZN reported $0M in revenue and ($9M) in net income.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Interactive charts & full statements →
| Income statement | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($9M) | ($4M) | ($10M) | ($15M) | — |
| Net Income | ($9M) | ($4M) | ($10M) | ($15M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — | — |
| Operating Income (EBIT) | ($3M) | ($2M) | ($1M) | ($3M) | ($1M) | — | — |
| Net Income | ($3M) | ($2M) | ($1M) | ($3M) | ($1M) | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Total Assets | $2M | $5M | $1M | $6M | — |
| Total Liabilities | $1M | $1M | $3M | $3M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALZN viewer.
About TickerBase · Data methodology & sources